Active, not recruitingPHASE2, PHASE3NCT02135042
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Studying Nasopharyngeal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NRG Oncology
- Principal Investigator
- Nancy LeeNRG Oncology
- Intervention
- Cisplatin(drug)
- Enrollment
- 685 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2031
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- The Kirklin Clinic at Acton Road, Birmingham, Alabama, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States
- Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
- Mills-Peninsula Medical Center, Burlingame, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Kaiser Permanente Dublin, Dublin, California, United States
- Fresno Cancer Center, Fresno, California, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- Memorial Medical Center, Modesto, California, United States
- Kaiser Permanente Oakland-Broadway, Oakland, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- Palo Alto Medical Foundation Health Care, Palo Alto, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02135042 on ClinicalTrials.govOther trials for Nasopharyngeal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06980038Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07362979Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaSun Yat-sen University
- RECRUITINGNANCT06796270Hypofractionated Radiotherapy for Nasopharyngeal CarcinomaThe Second Affiliated Hospital of Hainan Medical University
- RECRUITINGPHASE2NCT06059261Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.Chongqing University Cancer Hospital
- RECRUITINGNCT07376603IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk FeaturesQiaojuan Guo
- RECRUITINGPHASE3NCT07340515Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III TrialMan Hu
- RECRUITINGPHASE3NCT0732885440.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal CarcinomaMing-Yuan Chen
- RECRUITINGNCT07232680Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon ChemoradiotherapyCheng-En Hsieh